Jaygee Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 02-01-2025
- Paid Up Capital ₹ 0.10 M
as on 02-01-2025
- Company Age 46 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -100.00%
(FY 2022)
- Profit -131.82%
(FY 2022)
- Ebitda -75.74%
(FY 2022)
- Net Worth -4.98%
(FY 2022)
- Total Assets -5.56%
(FY 2022)
About Jaygee Pharmaceuticals
The Company is engaged in the Food And Beverages Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Statira Wadia, Wadia Farrokh, and Shirin Wadia serve as directors at the Company.
- CIN/LLPIN
U24200MH1978PTC020579
- Company No.
020579
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Aug 1978
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Jaygee Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shirin Wadia  | Director | 30-Aug-2024 | Current |
| Statira Wadia | Director | 09-Mar-1998 | Current |
| Wadia Farrokh | Director | 16-Dec-2003 | Current |
Financial Performance of Jaygee Pharmaceuticals.
Jaygee Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 100% decrease. The company also saw a substantial fall in profitability, with a 131.82% decrease in profit. The company's net worth dipped by a decrease of 4.98%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jaygee Pharmaceuticals?
Unlock access to Jaygee Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Sagitarius Ecospaces LlpActive 7 years 8 monthsStatira Wadia, Wadia Farrokh and 1 more are mutual person
- Nephronia Ecospaces LlpActive 4 years 11 months
Statira Wadia, Wadia Farrokh and 1 more are mutual person
- Bluegrass Ecospaces LlpActive 4 years 11 months
Statira Wadia, Wadia Farrokh and 1 more are mutual person
- Guzder Eco Sensitive Areas Conservation LimitedActive 19 years 1 month
Statira Wadia is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Jaygee Pharmaceuticals?
Unlock and access historical data on people associated with Jaygee Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jaygee Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jaygee Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
